Vividion Therapeutics, a clinical-stage biopharmaceutical company, has acquired Tavros Therapeutics, a precision oncology platform company, for an undisclosed sum.
Vividion is a wholly owned, independently operating subsidiary of Germany-based pharmaceutical and biotechnology company Bayer.
It uses novel discovery technologies to unlock high-value, undruggable targets and develop small-molecule precision therapeutics for cancers and immune disorders.
Vividion and Tavros have been working together for the last two years, to discover and develop novel precision therapeutics to mitigate cancer-causing proteins.
Vividion CEO Aleksandra Rizo said: “The addition of Tavros will expand and strengthen our chemoproteomics drug screening capabilities and open up a new target space to fuel the growing pipeline of novel therapies across oncology and immunology.
“We have already seen the power of combining Vividion’s platform and compound library with Tavros’s functional genomics capabilities in uncovering druggable vulnerabilities in tumour cells.”
Tavros is a precision oncology company that leverages its unique platform and synthetic lethal map to build an advanced pipeline of small-molecule drug candidates.
Its advanced bi-directional CRISPR-based synthetic lethality discovery engine, EVOLVE, can precisely and directly identify the paired genetic interactions.
Bayer said the acquisition advances the development of previously undruggable targets to improve outcomes for patients with significantly high unmet medical needs.
Tavros is expected to expand Vividion’s functional genomics expertise and capabilities.
It will bring unique methods for genomic screening to identify new target opportunities, as well as support discovery and translational efforts towards known targets.
Tavros will combine its platform with Vividion’s chemo proteomics expertise and capabilities to enhance efforts to generate potential drug targets across oncology and immunology.
Tavros CEO and co-founder Eoin McDonnell said: “We have enjoyed a highly productive partnership over the past two years and have seen the clear synergy between our platforms.
“We look forward to building on our success to date to develop novel small molecule therapeutics against elusive protein targets and maximise our ability to bring new treatment options to patients.”
